ATTAIN STUDY ACLIDINIUM PDF

The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD). David Singh, Eric D. Bateman, Paul W. Jones. The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease. Eric D. Bateman, David Singh, Paul W. Jones, Alvar. This paper presents results from a phase III study of longer duration (Aclidinium To Treat Airway obstruction In COPD patieNts; ATTAIN), which.

Author: Dushakar JoJogul
Country: Central African Republic
Language: English (Spanish)
Genre: Art
Published (Last): 20 October 2004
Pages: 358
PDF File Size: 10.17 Mb
ePub File Size: 9.57 Mb
ISBN: 436-7-93296-667-3
Downloads: 92595
Price: Free* [*Free Regsitration Required]
Uploader: Moogunris

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: Effect of formoterol alone and in combination with aclidinium on electrocardiograms in dogs. Discussion As noted in the current GOLD guidelines, tiotropium, aclidinium, and glycopyrronium can all be considered as appropriate options for maintenance treatment in the stable COPD patient. Global Initiative atudy Chronic Obstructive Lung Disease [webpage on the Internet] Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [updated Jan ] [Accessed November 12, ].

Minimal clinically important differences in COPD lung function. The subject of this review is a third LAMA, aclidinium bromide, which was approved as a twice-daily maintenance bronchodilator treatment. This showed that aclidinium improved the total score and the component scores breathlessness, chest symptoms, and cough and sputum significantly more than placebo Figure 7.

Subsequently, studies investigating higher doses and alternative dosing regimens were conducted, 2930 leading to two Phase III studies: Cochrane Database Syst Rev.

Aclidinium bromide, a long-acting antimuscarinic, does not affect QT aclidinoum in healthy subjects.

Aclidinium has been extensively evaluated in patients with COPD Table 1 29 — 39 and has also been the subject of a recent Cochrane systematic review. Week 12 trough FEV 1 change from baseline vs placebo: In the ACCORD COPD I study, 31 night-time and morning COPD symptoms were all significantly reduced among patients treated with aclidinium compared with those who received placebo Figure 5and the impact of breathlessness on early morning activities was also significantly reduced with aclidinium versus placebo Figure 6.

  DARK PASSIONS CTHULHUTECH PDF

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.

Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Glycopyrronium bromide is a synthetic quaternary ammonium compound, which has been used for many years to reduce secretions and block cardiac vagal reflexes before surgery. Three long-acting muscarinic antagonists LAMAs are now available in Europe, providing clinicians and patients with a choice of interventions, which is stkdy in COPD, which is clinically a heterogeneous disease. US Food and Drug Administration; Efficacy and safety Aclidinium has been extensively ahtain in patients with COPD Table 1 29 — 39 and has also been the subject of a recent Cochrane systematic review.

While additional studies are needed to evaluate its full clinical potential, aclidinium is an important part of this recent expansion of LAMA therapeutic options, providing clinicians and patients with an effective and well-tolerated COPD treatment.

A phase I, open-label, single-dose clinical trial.

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.

Author information Copyright and License information Disclaimer. Significant improvements were seen in breathlessness, health status, and COPD symptoms in the pivotal trials.

Preclinical studies have shown that aclidinium displays high affinity for all five muscarinic receptors, with kinetic selectivity for M 3 receptors over M 2and a shorter duration of action and a faster onset compared with tiotropium bromide. As noted in the current GOLD guidelines, tiotropium, aclidinium, and glycopyrronium can all be considered as appropriate options for maintenance treatment in the stable COPD patient. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.

Glycopyrronium bromide Glycopyrronium bromide is a synthetic quaternary ammonium compound, which has been used for many years to reduce secretions and block cardiac vagal reflexes before surgery. The low systemic bio-availability of aclidinium may be an advantage, but more data are needed, as this is a class of drugs with a generally low side-effect rate.

  HIPPING THE HOP PDF

There was a problem providing the content you requested

There were no statistically significant differences between the two aclidinium arms. Professor Paul Jones is the guarantor for this article, and takes sfudy for the integrity of the work as a whole. Dosing regimens and inhaler performance may be equally important in determining relative advantages of one drug over another.

Reproduced with permission of the European Respiratory Society: Tiotropium has been widely used over the last sthdy as once-daily maintenance therapy in stable COPD. Mean area under the FEV 1 curve 0—24 h time interval was 1. The clinical study data synthesis presented in the Cochrane review demonstrated significant improvements in transition dyspnea index eight trials, 4, patients and SGRQ seven trials, 4, patients with aclidinium therapy compared with placebo.

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

In conclusion, when considering new inhaled drugs, it is important to look beyond the chemical entity and its pharmacology. Aclidinium bromide for stable chronic obstructive pulmonary disease.

Open in a separate window. Breathlessness, health status, and COPD symptoms with aclidinium Significant improvements were seen in breathlessness, health status, and COPD symptoms in the pivotal trials.

The three LAMAs also provide patients with a choice, as each is delivered by a different device, and some patients may prefer one over another. Safety and tolerability of aclidinium bromide in patients with COPD: Efficacy and safety of twice-daily aclidinium bromide in COPD patients: Comparative safety of inhaled medications in patients with chronic obstructive pulmonary aclidiniumm